Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cells

Full text
de Almeida, Larissa Costa [1] ; Bauermeister, Anelize [2, 1] ; Rezende-Teixeira, Paula [1] ; dos Santos, Evelyne Alves [3] ; Beraldo de Moraes, Luiz Alberto [2] ; Machado-Neto, Joao Agostinho [1] ; Costa-Lotufo, Leticia Veras [1]
Total Authors: 7
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Av Prof Lineu Prestes 1524, BR-05508900 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Fac Philosophy Sci & Letters Ribeirao Preto, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Biomed Sci, Dept Cell Biol & Dev, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Biochemical Pharmacology; v. 168, p. 38-47, OCT 2019.
Web of Science Citations: 1

DNA-damaging agents are widely used in cancer therapy; however, their use is limited by dose-related toxicities, as well as the development of drug resistance. Drug discovery is essential to overcome these limitations and offer novel therapeutic options. In a previous study by our research group, pradimicin-IRD-a new polycyclic antibiotic produced by the actinobacteria Amycolatopsis sp.-displayed antimicrobial and potential anticancer activities. In the present study, cytotoxic activity was further confirmed in a panel of five colon cancer, including those with mutation in TP53 and KRAS, the most common ones observed in cancer colon patients. While all tested colon cancer cells were sensitive to pradimicin-IRD treatment with IC50 in micromolar range, non-tumor fibroblasts were significantly less sensitive (p < 0.05). The cellular and molecular mechanism of action of pradimicin-IRD was then investigated in the colorectal cancer cell line HCT 116. Pradimicin-IRD presented antitumor effects occurring after at least 6 h of exposure. Pradimicin-IRD induced statistically significant DNA damage (gamma H2AX and p21), apoptosis (PARP1 and caspase 3 cleavage) and cell cycle arrest (reduced Rb phosphorylation, cyclin A and cyclin B expression) markers. In accordance with these results, pradimicin-IRD increased cell populations in the subG(1) and G(0)/G(1) phases of the cell cycle. Additionally, mass spectrometry analysis indicated that pradimicin-IRD interacted with the DNA double strand. In summary, pradimicin-IRD exhibits multiple antineoplastic activities-including DNA damage, cell cycle arrest, reduction of clonal growth and apoptosis-in the HCT 116 cell line. Furthermore, pradimicin-IRD displays a TP53-independent regulation of p21 expression in HCT 116 TP53(-/-), HT-29, SW480, and Caco-2 cells. This exploratory study identified novel targets for pradimicin-IRD and provided insights for its potential anticancer activity as a DNA-damaging agent. (AU)

FAPESP's process: 18/17595-0 - Study of pradimicina-IRD molecular interaction with DNA and its tumor cell mechanism of action
Grantee:Larissa Costa de Almeida
Support type: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 14/50926-0 - INCT 2014: biodiversity and natural products
Grantee:Vanderlan da Silva Bolzani
Support type: BIOTA-FAPESP Program - Thematic Grants
FAPESP's process: 15/17177-6 - Integrative approach on the sustainable prospection of marine natural products: from diversity to anticancer compounds
Grantee:Leticia Veras Costa Lotufo
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/17648-4 - Integrative approach on the sustainable prospection of marine natural products: from diversity to anticancer compounds
Grantee:Anelize Bauermeister
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 17/24993-0 - Investigation of Stathmin 1 and microtubule instability in phenotype of hematological neoplasms
Grantee:João Agostinho Machado Neto
Support type: Regular Research Grants